JP2023553414A5 - - Google Patents

Info

Publication number
JP2023553414A5
JP2023553414A5 JP2023534245A JP2023534245A JP2023553414A5 JP 2023553414 A5 JP2023553414 A5 JP 2023553414A5 JP 2023534245 A JP2023534245 A JP 2023534245A JP 2023534245 A JP2023534245 A JP 2023534245A JP 2023553414 A5 JP2023553414 A5 JP 2023553414A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
group
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553414A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062850 external-priority patent/WO2022125925A1/en
Publication of JP2023553414A publication Critical patent/JP2023553414A/ja
Publication of JP2023553414A5 publication Critical patent/JP2023553414A5/ja
Pending legal-status Critical Current

Links

JP2023534245A 2020-12-11 2021-12-10 ドライ型加齢黄斑変性症(amd)治療用組成物 Pending JP2023553414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124695P 2020-12-11 2020-12-11
US63/124,695 2020-12-11
PCT/US2021/062850 WO2022125925A1 (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Publications (2)

Publication Number Publication Date
JP2023553414A JP2023553414A (ja) 2023-12-21
JP2023553414A5 true JP2023553414A5 (cg-RX-API-DMAC7.html) 2024-12-13

Family

ID=81974688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534245A Pending JP2023553414A (ja) 2020-12-11 2021-12-10 ドライ型加齢黄斑変性症(amd)治療用組成物

Country Status (10)

Country Link
US (1) US20240009168A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553414A (cg-RX-API-DMAC7.html)
KR (1) KR20230118158A (cg-RX-API-DMAC7.html)
CN (1) CN116867488A (cg-RX-API-DMAC7.html)
AU (1) AU2021396380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200346A1 (cg-RX-API-DMAC7.html)
IL (1) IL303592A (cg-RX-API-DMAC7.html)
MX (1) MX2023006677A (cg-RX-API-DMAC7.html)
WO (1) WO2022125925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
ES2969373B2 (es) 2022-10-14 2025-02-06 Igen Biolab Group Ag Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo
WO2025122753A2 (en) * 2023-12-08 2025-06-12 Cognition Therapeutics, Inc. Compositions and methods for the treatment of niemann-pick disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
BRPI0919920A2 (pt) * 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법

Similar Documents

Publication Publication Date Title
JP2017507122A5 (cg-RX-API-DMAC7.html)
JP2024510249A5 (cg-RX-API-DMAC7.html)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2010136665A (ru) Новые пиридиноны и пиридазиноны
JP2012530765A5 (cg-RX-API-DMAC7.html)
RU2419626C2 (ru) Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
RU2015106605A (ru) Соединения замещенных пиразолонов и способы использования
RU2010145463A (ru) Производные замещенного 2-фенилпиридина
RU2009115653A (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2023552610A5 (cg-RX-API-DMAC7.html)
JP2016509591A5 (cg-RX-API-DMAC7.html)
AR086972A1 (es) Procesos para preparar compuestos heterociclicos, que incluyen trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
JP2010538076A5 (cg-RX-API-DMAC7.html)
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
JP2014508720A5 (cg-RX-API-DMAC7.html)
RU2007148217A (ru) Получение производных n-фенил-2-пиримидинамина
JP2013525458A5 (cg-RX-API-DMAC7.html)
JP2007502804A5 (cg-RX-API-DMAC7.html)
JP2022533939A5 (cg-RX-API-DMAC7.html)
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
JP2004520282A5 (cg-RX-API-DMAC7.html)
JP2013539786A5 (cg-RX-API-DMAC7.html)
AR054787A1 (es) Derivados de piperidinas utiles como antagonistas de histamina h3